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Abstract
The digestive system is an environmental frontline involving digestive secretions, intestinal cell metabolism, and gut microbiome that significantly 
modulate multiple functions in organisms. Understanding the ‘gut-lung axis’, where gut residential microbiota play important roles, may help in 
the development of better prophylactics and intervention strategies for diseases caused by respiratory viruses, including coronavirus disease of 
2019 (COVID-19). Gastrointestinal symptoms are common in COVID-19 patients and are generally indicative of disease complications. As we 
have learned so far, diarrhea and gut dysbiosis during SARS-CoV-2 infection should not be ignored, as they can be used to distinguish pathways 
of dysregulation of the immune system and the regulatory pathways upstream and downstream of viral primary binding receptors such as ACE2. 
This review presents evidence of microbiome signatures in the gut and respiratory system that may predict the severity and long-term outcomes 
of COVID-19. Understanding the factors (such as pro-inflammatory trends, modulation of metabolite availability, and impact on cell signaling and 
pathogenic properties) translating the effect of microbiome composition on the severity of respiratory infections should help in the development of 
new approaches for health monitoring, disease prevention, and treatment.
Keywords: GM • Microbiome • COVID-19 • SARS-CoV-2 • Dys-biosis • ACE2 • Immune system • Gut-lung axis
Abbreviations: SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2 • SARS: Severe Acute Respiratory Syndrome •  COVID-19: 
Coronavirus Disease of 2019 •  MERS: Middle East Respiratory Syndrome •  RSV: Respiratory Syncytial Virus •  GM: Gut Microbiome •  GI: 
Gastrointestinal •  IBD: Irritable Bowel Disease •  ACE2: Angiotensin Converting Enzyme 2 •  IFN-I: Type I Interferon (IFN-α) •  B(O)AT1: Sodium-
dependent Neutral Amino Acid Transporter •  mTOR: The Mammalian Target of Rapamycin.
Introduction
The digestive system is an environmental frontline involving digestive 
secretions, intestinal cell metabolism, and gut microbiome (GM) [1,2] that 
significantly modulate multiple organism’s functions organisms [3]. Nutrients 
and prebiotics provide substrates for a dynamic GM, which is estimated to 
consist of over 1000 different microbial species belonging to five predominant 
phyla: Firmicutes, Bacteroidetes, Actinobacteria, Verrucomicrobia, and 
Proteobacteria [4-7]. Approximately 400 identified species are strictly anaerobic 
and hence will generally be found in mucosal regions such as the oral cavity 
and the gastrointestinal (GI) tract [2,6].
Two thirds of the GM is considered an individual-specific ‘fingerprint’ [2,8]; 
however, there are correlations found between GM composition and diet [1,9-
11], geography, ethnicity [11-15], age, and longevity of the host [10,14-17], and 
certain diseases [8,18-22]. GM characteristics of members of the same family 
cluster in functional and taxonomic space, stressing the role of environmental 
and genetic factors in the evolution of an individual’s GM [23].
Gut virome composition also appears to be unique to and varies with 
people’s age and geography, with few viral populations shared within a subset 
of people. There are 33,242 unique viral populations (97.7% of which are 
phages) that have been identified in the human gut [24]. As is the case with 
the microbiome, consistent variations in viral diversity could also be seen in 
healthy versus sick participants [25].
The current global COVID-19 pandemic [26] is caused by a beta 
coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), 
that in the most vulnerable individuals can cause an immune response 
resembling cytokine storm syndrome [27], a dysregulated secretion of cytokines 
that triggers systemic inflammation and hypercoagulation, and, in children, a 
multisystem inflammatory syndrome that resembles Kawasaki disease [28]. 
Approximately 20% of patients with COVID-19 develop serious complications, 
often accompanied by fatal acute respiratory distress syndrome. 
Increasing evidence points to an intimate relationship between the 
gastrointestinal and respiratory tracts, which is known as the ‘gut-lung axis’ [29-
31]. The intestinal flora is involved in host nutrient absorption and metabolism 
and has a profound impact on all organ systems, human health, and disease 
[7,32–35].
However, intestinal microflora disorders reduce host antiviral immune 
responses, thereby aggravating the lung damage caused by these infections 
[36]. Changes in the lung microbiota were identified in COVID-19 patients, 
with a shift towards bacteria found in the intestinal tract correlating with the 
onset of acute respiratory distress syndrome. Probiotics have already been 
recommended for anti-viral therapy and prophylactics [37,38].
Literature Review
In this review, we bring together data pointing to the potential significance 
of modulation of the gut microbial community and its functional influence on 
the organism’s immunity and resistance to prophylactics and treatment of 
COVID-19 disease. These factors should be addressed as we prepare for 
future challenges.
COVID-19 gastrointestinal manifestations
GI symptoms in COVID-19 patients are generally indicative of 
complications. However, they are common in these patients, with a meta-
analysis showing that the symptoms were present in 17.6% of infected patients 
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[39,40]. Similarly, approximately 25% of patients with SARS and MERS 
exhibited GI symptoms [41,42]. 
Studies have detected SARS-CoV-2 RNA in anal swabs and stool 
samples from almost 50% of patients with COVID-19 [43-46]. mRNA analysis 
demonstrated that the duration of viral shedding from stool was longer than 
that from respiratory samples [47], suggesting that the digestive tract might 
be a site for virus replication and activity. Prolonged digestive symptoms, 
especially diarrhea, are negatively correlated with gut microbiota richness 
and composition [48,49], and are accompanied by elevated levels of fecal 
calprotectin, an indicator of inflammatory responses in the gut [50]. It should, 
however, be noted that gut microbiome dysbiosis is also characteristic of 
diabetes, obesity, autoimmune, and aging-related diseases, all of which are 
associated with an increased risk of severe COVID-19 [13]. 
GM dysbiosis is associated with COVID-19 disease
Comorbidities commonly accompanying severe COVID-19 are known to 
be associated with alterations in bacterial taxa from the phyla Bacteroidetes 
and Firmicutes [51-54], which were reported to regulate angiotensin-converting 
enzyme 2 (ACE2) expression in rodents [55]. Assessment of GMs of COVID-19 
hospital patients conducted in China [56] showed that the abundance of 
Coprobacillus, Clostridium ramosum, and Clostridium hathewayi species 
positively correlate, while the abundance of Faecalibacterium prausnitzii (an 
anti-inflammatory bacterium) negatively correlates with COVID-19 severity. 
During hospitalization, abundancies of Bacteroides dorei, Bacteroides 
thetaiotaomicron, Bacteroides massiliensis, and Bacteroides ovatus were 
inversely correlated with SARS-CoV-2 load in fecal samples from the patients. 
However, gut dysbiosis persisted even after clearance of SARS-CoV-2 from 
the throat and resolution of respiratory symptoms.
Changes in GM composition may be indicative of shifts in nutritional 
availability in the gut, which could be due to the diet, pharmacological 
interventions, or absorptive properties of the gut endothelium. Fecal samples 
with high SARS-CoV-2 mRNA load had an abundance of bacterial species 
with higher capacity for glycolysis, de novo nucleotide synthesis, and 
amino acid biosynthesis (e.g., Collinsella aerofaciens, Collinsella tanakaei, 
Streptococcus infantis, Morganella morganii), whereas fecal samples with 
low-to-none SARS-CoV-2 mRNA had a higher ratio of short-chain fatty acid-
producing bacteria [57,58] of the Parabacteroides, Bacteroides, Alistipes, and 
Lachnospiraceae genera [59]. Another important finding was the significant 
depletion of butyrate-producing bacteria in H1N1 patients versus healthy 
controls [60,61], suggesting that butyrate may be involved in the modulation 
of inflammation during viral pneumonia. This is supported by the observation 
that a high-fiber diet, which increases the production of short-chain fatty 
acids, enhances the antiviral CD8+ T-cell immune response during influenza 
virus infection, attenuates neutrophil-mediated lung injury, and consequently 
improves survival [36,62]. MRx-4DP0004, a strain of the butyrate-producing 
bacterium Bifidobacterium breve, originally developed for asthma treatment 
[63], has shown the potential to downregulate specific pathological aspects of 
the hyper-inflammatory response while maintaining the appropriate antiviral 
response. However, significantly reduced levels of butyrate producers were 
linked to overgrowth of pathogenic bacteria and increased intestinal mucosal 
permeability and endotoxin intoxication and, consequently, inflammation with 
cytokine release [64-66]. Recent studies further suggest that gut microbiome 
composition may predict a predisposition to severe COVID-19 due to a hyper-
inflammatory response [49].
Gut microbiome and viral infections shift in GM composi-
tion
An increase in the proinflammatory component in GM has also been 
observed for other respiratory viruses such as influenza [67]. In a lemur model, 
several commensal taxa, essential for a healthy gut microbiome, decreased, 
whereas the abundance of potential pathogens, such as Neisseria, increased 
upon adenovirus infection [68].
The clinical manifestations and transmission routes of seasonal influenza 
A (H1N1) are similar to those of COVID-19 [69], and a comparison of the 
microbiota in these two diseases was of interest from etiological and diagnostic 
perspectives. The microbial signature associated with detectable levels of 
SARS-CoV-2 mRNA was similar to that of other respiratory viruses such as 
influenza and respiratory syncytial virus (RSV) (ignoring the small sample size 
of the study) [70]. However, patients with H1N1 displayed lower diversity and 
different overall microbial composition compared with COVID-19 patients, and 
biomarkers were proposed for distinguishing the two cohorts [71].
COVID-19 patients still had significantly reduced GM bacterial diversity, 
significantly higher relative abundance of opportunistic pathogens such as 
Streptococcus, Rothia, Veillonella, and Actinomyces, and lower relative 
abundance of beneficial symbionts, compared with healthy controls. Changes 
in the enteric environment and immune factors caused by Actinomyces, 
particularly, were shown to aggravate the damage caused by inflammatory 
bowel disease [60,72], and an association of Actinomyces with COVID-19 
infection may also have a prognostic value. 
Compared with healthy individuals, levels of Agathobacter, 
Fusicatenibacter, Roseburia, and Ruminococcaceae UCG-013 in COVID-19 
patients were depleted and negatively correlated with levels of inflammatory 
markers (CRP, procalcitonin, or D-dimer). Moreover, CRP and D-dimer levels 
were positively correlated with COVID-19–enriched bacteria (Streptococcus, 
Rothia, Veillonella, and Actinomyces). In the H1N1 cohort, there was a 
positive correlation between inflammatory cytokines; IL-2, IL-4, and IL-6, and 
abundance of Finegoldia, Anaerococcus, Peptoniphilus, Intestinibacter, and 
Prevotella genera [71].
Understanding whether the composition of the GM can be modified to 
improve the outcome of viral respiratory infections, particularly in COVID-19 
patients, is of great significance.
Immune system modulation by gut microbiome in COVID-19 
and other viral diseases
One of the ways in which microbiota can be involved in disease progression 
is by affecting the inflammatory state of the gut and the systemic levels of 
proinflammatory cytokines.
Higher abundance of Klebsiella, Streptococcus, and Ruminococcus 
genera correlated with elevated levels of proinflammatory cytokines and 
increased disease severity, while increased levels of Lactobacillus species 
correlated with higher levels of anti-inflammatory IL-10 and improved 
disease prognosis [49]. Cases of COVID-19-induced Kawasaki disease-like 
complications in young children [28,73] were also associated with dysbiotic 
gut microbiome, with increased levels of Streptococcus and decreased levels 
of Lactobacillus species compared with healthy children [74]. Compared with 
healthy individuals, COVID-19 patients had significantly higher systemic levels 
of IL-6 and TNF-α, and levels of cytokines IL18 and IgA in the gut were also 
affected by COVID-19 infection [75]. High IL18 and IgA levels correlated with 
overrepresentation of the previously mentioned Streptococcus genera, as well 
as Clostridium and Bifidobacterium. Increased abundance of Lactobacillus 
was correlated with high IL18 expression and poor prognosis, as well as a lack 
of the genera Bacteroidetes, Roseburia, Faecalibacterium, Coprococcus, and 
Parabacteroides in COVID-19 patients relative to healthy controls [75].
The proinflammatory gut environment is characteristic of patients suffering 
from a range of conditions, including diabetes, obesity, irritable bowel disease 
(IBD), and high blood pressure, which are typically correlated with the severity 
of COVID-19. One can expect some degree of causation between GM 
composition and the disease-promoting environment; however, the vector in 
the link still needs to be validated in larger patient cohorts or in an experimental 
setting (although this option is more problematic).
Both innate and adaptive immune system responses are triggered by 
SARS-CoV-2 infection. However, in severe COVID-19 patients, the numbers 
of B cells, CD4+ and CD8+ T cells, and monocytes are lower [76,77]. GM is 
a known modulator of the immune system [78,79], and the immune system 
plays a leading role in gut colonization by microbiota, as the development 
of regulatory T cells and innate lymphoid cells help maintain gut and lung 
homeostasis. Microbial metabolites regulate the host immune system [80-83] 
and may also participate in the immune response triggered by viral replication 
in the gut.
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Butyrate and other short-chain fatty acids and desaminotyrosine produced 
by Bacteroidetes and/or Clostridium [81,84], for instance, can enhance 
influenza-specific CD8+ T-cell function [78] and Type I interferon (IFN-I) 
signaling in macrophages, increasing protection against influenza infection 
[85-88]. Microbiota-derived acetate also protected against respiratory syncytial 
virus infection through an interferon response in mice [65]. The typical gut 
microbiota also enhances antiviral immunity by increasing the number of 
immune cells and decreasing immunopathology.
Respiratory viruses are known to influence microbial composition in the 
lung and intestines. Respiratory influenza infection, for instance, causes 
intestinal injury when lung injury occurs by recruiting lung-derived CCR9+CD4+ 
T-cells to the small intestine and stimulating the production of interferon-γ by 
these cells [88,89]. Microbiota-driven signals triggered the IFN-I response in 
the lung stroma as a defense against early viral infection.
Influenza-infected individuals may also develop GI symptoms as observed 
in COVID-19 patients [89], although replication of the influenza virus occurs 
almost entirely in the respiratory system. It was demonstrated that IFN-I 
molecules produced in the lungs supported a depletion of obligate anaerobic 
bacteria and enrichment of Enterobacteriaceae in the gut [61], which could have 
been the cause of the observed proinflammatory dysbiotic gut environment 
[61], promoting further virus infectivity.
Role of ACE2 in the gut microbiome shifts during COVID-19 
A cell surface receptor, angiotensin-converting enzyme 2 (ACE2), is 
associated with cardiopulmonary disease, and alterations in the gut and/or 
lung microbiome have recently been suggested to play a role in this pathology 
[90,91]. Single-cell transcriptome analysis showed that ACE2 was highly 
expressed in lung alveolar epithelial type II (AT2) cells, stratified epithelial cells 
in the upper esophagus, and enterocytes in the ileum and colon [92]. ACE2 
expression is downregulated in patients during SARS infection [93], and ACE2 
was confirmed as the target of SARS-CoV-2 [94-96]. 
A dysbiotic gut environment and epithelial inflammation cause an 
increase in the levels of ACE2, affecting dietary amino acid homeostasis, 
Figure 1. Factors involved in the crosstalk between viral infections and GM. ACE2 regulates the intestinal uptake of tryptophan, mediated by B(0)AT1. Tryptophan stimulates the 
secretion of antimicrobial peptides (AMPs) through the mTOR pathway. Antimicrobial peptides can influence the composition of the gut microbiota by inhibiting the propagation of 
nonresident microbiota (red ovals). Butyrate-producing bacteria (green ovals) stimulate macrophages, dendritic cells (IC-immune cells), and T cells, and the production of IFN-I and 
anti-inflammatory interleukins. SARS-CoV-2 (red circle) binds to ACE2 and inhibits the activity of the associated transporters, breaking the balance in microflora abundancies. ACE2, 
Angiotensin-converting enzyme 2; IFN-I, Type I interferon (IFN-α); B(O)AT1, Sodium-dependent neutral amino acid transporter; mTOR, The mammalian target of rapamycin.
innate immunity, and gut microbial ecology [49,97]. Expression of ACE2 is 
regulated by gut bacteria; representative species of Bacteroides genus, for 
instance, are known to downregulate the expression of ACE2 in the murine 
gut [98]. Proinflammatory gut microbiome, on the contrary, can elevate ACE2 
expression and promote conditions favorable for SARS-CoV-2 infection of the 
gut epithelium [99], from where it can spread through the body [100,101]. In 
turn, by binding to ACE2, SARS-CoV-2 may interfere with nutrient absorption 
and disrupt intestinal homeostasis (Figure 1). ACE2 regulates the activity of the 
sodium-dependent neutral amino acid transporter B(0)AT1, which controls the 
intestinal uptake of tryptophan [97,102]. Tryptophan regulates the expression 
of antimicrobial peptides, an important component of the homeostatic 
regulation of GM composition, through the mammalian target of rapamycin 
(mTOR) pathway (Figure 1) [103,104]. ACE2 downregulation, therefore, 
should decrease the secretion of antimicrobial peptides, leading to increased 
pathogen survival and gut dysbiosis. ACE2-dependent regulation of the 
microbiota may explain the occurrence of diarrhea in SARS-CoV and SARS-
CoV-2 infections [54,96]. ACE2 might also be associated with cardiopulmonary 
pathology via alterations in the gut and/or lung microbiome [90].
It is worth noting that, although ACE2 facilitates viral entry at the epithelial 
surface, it offers protection against acute lung injury. The ACE2 functional circuit 
[91] can be carefully adjusted to confront SARS-induced tissue injury, and it is 
becoming clearer that GM plays some part in this homeostatic mitigation [105]. 
Clinical trials have shown that administration of ACE2 can reduce systemic 
inflammation [106].
Gut-Lung axis and Lung microbiomes
COVID-19 associated with GM-led processes crosstalk is summarized in 
Figure 2. Lung microbiome composition also undergoes a shift during viral 
infection, and, unexpectedly, typical GM resident bacteria become abundant in 
the lung microbiome in severe cases of the disease.
Gut-associated Bacteroides species were found in the lungs of 41% of acute 
respiratory syndrome patients compared with only 3.8% of healthy controls, and 
were also positively correlated with elevated levels of inflammatory markers in 
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Figure 2. Role of the gut-lung axis in COVID-19. Red arrows represent suppression and 
blue arrows represent activation of downstream processes.
Table 1. Statements and evidences.
Main Statements, Evidence References
Compositions of GM and lung commensal microbiomes correlate with systemic changes in a state of immune system
GM influences immune response to respiratory viral infections (gut-lung axis). [37,38]
A balance of the microbiota is necessary for homeostasis: a comprehensive study of immune system modulation by GM in mice. [55]
Lung commensal microbiota critically regulates the generation of virus-specific CD4 and CD8 T-cells and antibody responses following respiratory 
influenza virus infection. [36]
Gut-associated Bacteroides presence in lung positively correlates with elevated inflammatory markers in plasma. [107]
GM composition changes in adenovirus and H1N1 infections. [68-71]
Lung-infection derived CCR9+CD4+ T-cells can be recruited to the small intestine. [88,89]
Influenza virus infection induces microbiota-mediated Th17 cell-dependent inflammation. [88]
IFN-I molecules produced in the lung supported a depletion of obligate anaerobic bacteria and enrichment of Enterobacteriaceae in the gut. [61]
GM composition and systemic immune markers correlate. [49,50,71,36,62,73,75-83]
Microbiota signatures in the gut and respiratory system may predict severity and long-term outcomes in COVID-19 patients
COVID-19 severity negatively correlates with Bacteroides, Firmicutes species abundancies. [49,51-54,73,74]
COVID-19 severity positively correlates with Coprobacillus, Clostridium ramosum, and Clostridium hathewayi . [56]
Negative correlations with Faecalibacterium prausnitzii, Bacteroides species. [56]
Bacteroidesgenus, Streptococcus genus and Clostridiales order were negatively correlated with the inflammatory cytokines, Ruminococcus genus, 
Blautiagenus and Lactobacillus genus showed positive associations. [49]
IL-2, IL-4, and IL-6 levels correlate with abundancies of Finegoldia, Anaerococcus, Peptoniphilus, Intestinibacter, and Prevotella genera. [71]
GM may play a causative role in gut-lung axis
GM modulates absorption of nutrients that may play a role in aetiology of systemic or organ pathologies. [29- 31,32-35,57]
Microbial metabolites (short-chain FA, desaminotyrosine ) regulate the immune system. [49,58,64,65, 78,80-87]
GM modulates host's immune system. [49,60-66]
GM effects ACE2 expression in the gut. [90,97,98]
Intestinal microflora disorders reduce host antiviral immune response. [36,32-35]
Changes in GM composition may effect viral infection outcome
Immune system modulation is an intermediate step in the gut-lung axis [60-66]
Nutrient absorption and intestinal microflora disorders reduce host antiviral immune response. [29- 31,32-35,36]
Immune system modulations in viral pneumonia correlate with the GM composition. [36,49,62]
Bifidobacterium breve positively modulates an outcome of viral pneumonia. [65]
dysbiosys causes changes in intestinal permeability and endotoxin intoxication. [64,65]
GM composition shifts are linked to hiperinflammatory response. [49]
Influenza-specific CD8+ T-cell function and Type I interferon (IFN-I) signalling in macrophages are associated with GM signalling. [49,62,65,78,85-88]
IL18, IGA levels can be affected by GM Furmicutes abundancies. [49,75]
Microbial metabolites regulate immune system. [49,64,80-83]
IL-2, IL-4, and IL-6 systemic levels correlate to Finegoldia, Anaerococcus, Peptoniphilus, Intestinibacter, and Prevotella abundancies [71]
ACE receptors expression is influenced by GM and, in their turn, influence GM composition [90,97,98]
Pre- and probiotics therapies may be complementary to vaccines, treatment, and during patients’ rehabilitation
Richness of GM composition is decreased in pathologies associated with a viral infection severity. [3,37,38,48,49]
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plasma [107]. The relative abundances of opportunistic pathogens such as 
Streptococcus, Rothia, Veillonella, Erysipelatoclostridium, and Actinomyces, 
were also increased in the lungs of COVID-19 patients. Among these, Rothia 
is already known to contribute to the pathogenesis of pneumonia, especially 
in immune compromised individuals [108]. Streptococcus and Rothia were 
also associated with susceptibility to secondary bacterial lung infection in 
patients with avian H7N9 virus infection [109], and the opportunistic pathogens 
Prevotella, Finegoldia, and Peptoniphilus, were enriched in lung microbiomes 
of H1N1 patients [60,71].
Discussion 
The severity of COVID-19 is associated with gastrointestinal symptoms 
[39,40,45], and we can suggest with high confidence that the digestive tract 
may be a site for virus replication and activity [43-47].
Prolonged diarrhea in COVID-19 patients is negatively correlated with 
gut microbiota richness and composition [48,49] and positively correlated 
with markers of ongoing inflammation [50]. Such associations are typical 
of dysbiosis, and dysbiosis is typical in diabetes, obesity, and autoimmune 
and aging-related diseases, which are comorbidities associated with severe 
COVID-19 outcomes [13,51-54]. Modulation of some of the listed diseases by 
pre- and probiotics has already been considered and shown to be successful 
[7,9,16,19-21,31,51-54]. We suggest that a similar approach may be effective 
with respect to prophylactic, and treatment of COVID-19 and other viral 
diseases [36-38,62, 66,90,96] as well as along the vaccination [110].
Alterations in Bacteroidetes and Firmicutes [28,49,51-54,71,74] taxa 
were the most common in severe COVID-19 cases, with an increase in the 
abundance of species relying on their own basic nucleotide and amino acid 
biosynthesis and glycolysis, and a decrease in the abundance of short-fatty 
acid producers [56–59]. The latter are also known to possess anti-inflammatory 
properties [60-66,71,78, 81-87], and modulate ACE2 receptor expression 
and amino acids metabolism (Figure 1) in the gut lining [49,55,97,98]. Thus, 
fiber-based diets, butyrate-rich fermented products, enrichment of a diet for 
particular cofactors involved in butyrate-generating pathways, and decreased 
sugar intake would play beneficial roles in GM-led protection from inflammation. 
ACE2 and its inhibitors have been explored as potential targets [90,97] and 
targeting of amino acid transport and biosynthesis in bacteria or amino acid 
supplementation in the host [49,97]  can be also considered.
Changes in the composition of GM may result in loss of antiviral resistance 
and respiratory system complications [55,83,85,87]. However, respiratory viral 
infections may also lead to changes in GM composition [89,90] (Figure 2). 
Interesting correlation data [36,51-59,68-71,75] suggest that a link exists 
between the niches (gut-lung and gut-immune system); however, the causative 
vectors of most observed correlations have not yet been defined. We propose 
that the complex system of cross-regulation in the case of GM-led pathology 
(Figure 2) may be modulated by careful targeting of immune components (such 
as proinflammatory interleukins, for instance). The main evidence supporting 
our statement has been collated and presented in Table 1 for evaluation.
Conclusion
We believe that further understanding of the physiological impact of 
the ‘gut-lung axis’ may help in the development of better prophylactic and 
intervention strategies for COVID-19 and other diseases caused by respiratory 
viruses. The dysbiosis manifestation and microbiota signatures in the gut 
and respiratory system, associated with higher mortality risk and long-term 
outcomes in COVID-19 patients, may be used in health monitoring during and 
after epidemics and be addressed by new pre- and probiotics therapies.
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